Trovagene (TROV) Announces Outperformance of Tissue Biopsy with Urine-Based PCM for EGFR T790M; Data Presented at ESMO-IASLC
Tweet Send to a Friend
Trovagene (NASDAQ: TROV) announced that clinical data presented at the 2015 European Lung Cancer Conference (ELCC) demonstrate that its urine-based ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
